Corbus Pharmaceuticals Holdings, Inc. (CRBP) revenue
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported revenue of $881.71K in fiscal 2021 (the year ended December 31, 2021). That is 77.6% lower than the $3.94M of fiscal 2020. Figures as of 18 Nov 2026, 12:38 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Revenue, fiscal 2021
- $881.71K
- Change on fiscal 2020
- −77.6%
- Growth, 5 years
- −14.3% a year
- Highest on record
- $36.14Mfiscal 2019
- Lowest on record
- $648.38Kfiscal 2015
- Fiscal years on record
- 72015–2021
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Corbus Pharmaceuticals Holdings, Inc. revenue, in more detail
Over the five fiscal years to 2021 revenue shrank at a compound 14.3% a year. Across the 7 fiscal years on record (2015–2021), the highest was $36.14M in fiscal 2019 and the lowest $648.38K in fiscal 2015.
Revenue by fiscal year
Corbus Pharmaceuticals Holdings, Inc. revenue, year by year
| Fiscal year | Revenue | Change | Year ended |
|---|---|---|---|
| 2021 | $881.71K | 77.6% down | |
| 2020 | $3.94M | 89.1% down | |
| 2019 | $36.14M | 649.5% up | |
| 2018 | $4.82M | 97.6% up | |
| 2017 | $2.44M | 27.7% up | |
| 2016 | $1.91M | 194.8% up | |
| 2015 | $648.38K | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
How to read it
Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.
Corbus Pharmaceuticals Holdings, Inc., figure by figure
- Corbus Pharmaceuticals Holdings, Inc. market cap
- Corbus Pharmaceuticals Holdings, Inc. earnings
- Corbus Pharmaceuticals Holdings, Inc. earnings per share (EPS)
- Corbus Pharmaceuticals Holdings, Inc. P/E ratio
- Corbus Pharmaceuticals Holdings, Inc. P/S ratio
- Corbus Pharmaceuticals Holdings, Inc. P/B ratio
- Corbus Pharmaceuticals Holdings, Inc. free cash flow
- Corbus Pharmaceuticals Holdings, Inc. operating margin
- Corbus Pharmaceuticals Holdings, Inc. dividend
- Corbus Pharmaceuticals Holdings, Inc. shares outstanding
- Corbus Pharmaceuticals Holdings, Inc. total debt
- Corbus Pharmaceuticals Holdings, Inc. cash on hand
- Corbus Pharmaceuticals Holdings, Inc. total assets
- Corbus Pharmaceuticals Holdings, Inc. return on equity (ROE)
- Corbus Pharmaceuticals Holdings, Inc. return on invested capital (ROIC)
Corbus Pharmaceuticals Holdings, Inc. (CRBP) overview: price, valuation and scorecard
Corbus Pharmaceuticals Holdings, Inc. revenue: questions and answers
What is Corbus Pharmaceuticals Holdings, Inc.'s revenue?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported revenue of $881.71K in fiscal 2021 (the year ended December 31, 2021). That is 77.6% lower than the $3.94M of fiscal 2020.
What is the growth rate of Corbus Pharmaceuticals Holdings, Inc.'s revenue?
Over the five fiscal years to 2021 revenue shrank at a compound 14.3% a year.
What are the highest and lowest revenue figures on record for Corbus Pharmaceuticals Holdings, Inc.?
Across the 7 fiscal years on record (2015–2021), the highest was $36.14M in fiscal 2019 and the lowest $648.38K in fiscal 2015.
How is Corbus Pharmaceuticals Holdings, Inc.'s revenue calculated?
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Corbus Pharmaceuticals Holdings, Inc. it is on record here for 7 fiscal years, 2015 to 2021.
Fiscal years are named for the calendar year they end in.
Learn: revenue
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Corbus Pharmaceuticals Holdings, Inc. (CRBP) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/CRBP/revenue
Underlying data: the company's filings with the SEC and Yahoo Finance.